Janux Therapeutics, Inc. (JANX) DCF Valuation

Janux Therapeutics, Inc. (JANX) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Janux Therapeutics, Inc. (JANX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our (JANX) DCF Calculator enables you to evaluate Janux Therapeutics, Inc. valuation using real-world financial data, offering complete flexibility to modify all essential parameters for enhanced projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 3.6 8.6 8.1 10.0 12.3 15.2 18.8 23.2
Revenue Growth, % 0 0 0 136.79 -6.14 23.46 23.46 23.46 23.46 23.46
EBITDA -3.8 -4.8 -32.8 -66.3 -71.0 -2.0 -2.5 -3.0 -3.8 -4.6
EBITDA, % 100 100 -902.28 -769.28 -878.68 -20 -20 -20 -20 -20
Depreciation .0 .0 .1 .8 2.0 4.7 5.8 7.2 8.9 11.0
Depreciation, % 100 100 3.11 9.77 24.19 47.41 47.41 47.41 47.41 47.41
EBIT -3.8 -4.8 -32.9 -67.1 -73.0 -2.0 -2.5 -3.0 -3.8 -4.6
EBIT, % 100 100 -905.39 -779.04 -902.87 -20 -20 -20 -20 -20
Total Cash .7 7.8 375.0 327.0 344.0 10.0 12.3 15.2 18.8 23.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 8.0 .0 .0 .0
Account Receivables, % 100 100 0 0 0
Inventories .0 .0 -.2 -.7 .0 3.7 4.6 5.7 7.0 8.6
Inventories, % 100 100 -5.5 -8.13 0 37.27 37.27 37.27 37.27 37.27
Accounts Payable .3 .4 2.5 2.2 2.4 6.4 8.0 9.8 12.1 15.0
Accounts Payable, % 100 100 67.58 25.07 29.99 64.53 64.53 64.53 64.53 64.53
Capital Expenditure .0 .0 -1.5 -6.4 -1.9 -2.8 -3.4 -4.2 -5.2 -6.4
Capital Expenditure, % 100 100 -40.75 -74.84 -22.89 -27.69 -27.69 -27.69 -27.69 -27.69
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -4.0 -3.8 -32.8 -57.6 -73.0 -1.8 -2.3 -2.8 -3.5 -4.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -3.7 -11.6 -24.0 -63.0 -73.3 -3.6 -.2 -.2 -.2 -.3
WACC, % 20.88 20.87 20.88 20.87 20.88 20.88 20.88 20.88 20.88 20.88
PV UFCF
SUM PV UFCF -3.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value -2
Present Terminal Value -1
Enterprise Value -4
Net Debt 5
Equity Value -9
Diluted Shares Outstanding, MM 44
Equity Value Per Share -0.21

What You Will Get

  • Real JANX Financial Data: Pre-filled with Janux Therapeutics' historical and projected data for precise analysis.
  • Fully Editable Template: Easily modify key inputs such as revenue growth, WACC, and EBITDA %.
  • Automatic Calculations: Instantly see Janux Therapeutics' intrinsic value update based on your adjustments.
  • Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for accurate DCF results.
  • User-Friendly Design: Intuitive structure and clear instructions suitable for all experience levels.

Key Features

  • Innovative Drug Development Pipeline: Focus on unique therapeutic approaches for cancer treatment.
  • Robust Clinical Trial Management: Comprehensive tracking and analysis of ongoing clinical studies.
  • Customizable Financial Projections: Adjust revenue forecasts, R&D expenses, and market penetration rates.
  • Integrated Market Analysis: Evaluate competitive landscape and market opportunities for [JANX].
  • Dynamic Reporting Tools: Visual dashboards present key performance indicators for informed decision-making.

How It Works

  • Download: Obtain the pre-configured Excel file containing Janux Therapeutics, Inc.'s (JANX) financial data.
  • Customize: Modify projections, such as revenue growth, EBITDA %, and WACC as per your analysis.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time for accurate insights.
  • Test Scenarios: Generate various forecasts and instantly compare the results.
  • Make Decisions: Leverage the valuation findings to inform your investment choices.

Why Choose This Calculator for Janux Therapeutics, Inc. (JANX)?

  • Accurate Data: Utilize real Janux financials for dependable valuation outcomes.
  • Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you from building from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Easy-to-navigate design and guided instructions cater to users of all experience levels.

Who Should Use Janux Therapeutics, Inc. (JANX)?

  • Investors: Gain insights into innovative cancer therapies with our cutting-edge research and development data.
  • Healthcare Analysts: Streamline your analysis with comprehensive reports on our pipeline and market potential.
  • Consultants: Easily tailor presentations or reports using our detailed product information and market strategies.
  • Biotech Enthusiasts: Enhance your knowledge of breakthrough therapies and their impact on patient care.
  • Educators and Students: Utilize our resources as a practical case study in biotechnology and pharmaceutical courses.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Janux Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Janux Therapeutics, Inc. (JANX).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.